Well, one thing is that we actually did not file any patents for our vaccine. It's free and open to anybody who wants to scale it up and produce it. We do this for practical reasons, because the filing of patents is so expensive, and our biggest concern is access. We provide non-exclusive licence for our vaccines for just a minimal licensing fee, and then you have the opportunity to scale it up and produce it. We put everything in the public domain, meaning we publish every step of the way, so that nobody can actually block us either. It has worked very well for us for our global health vaccines for schistosomiasis and Chagas disease, and we've taken the same approach for COVID-19 vaccines.
Again, intellectual property for us is not the biggest barrier. It's the fact that most countries just don't have the resources and trained human capital to scale it up. That's why I say, with respect to waiving intellectual property around mRNA vaccines, do not expect that all of a sudden you're going to see lots of mRNA vaccines around. There is an enormous learning curve that's required in order to produce it. If you were serious about having other groups starting to make mRNA vaccines, you would have to ask the Pfizer and Moderna people who have the experience now in scaling this up to actually enter into plants with organizations to help them learn how to produce this at that large scale. That's why I say that waiving the patents could be useful in the long run and it may even have some short-term use, but if I were to rank the top five priorities right now for vaccinating the world, I don't even know that waiving the patents would be in the top five.